Pittsburgh, PA Clinical Trials Report — June 2026

For Pittsburgh residents considering participation in clinical research, June 2026 presents a mix of urgent opportunities and significant new avenues for contributing to medical science. Across Pittsburgh, PA, a notable number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 78 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 13 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Act Now: Trials Nearing Conclusion

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• NSCLC (3 trials)
• Chronic pain (3 trials)
• Cancer (3 trials)
• Melanoma (2 trials)
• Heavy drinking (2 trials)
• HNSCC (2 trials)
• Cardiovascular diseases (2 trials)
• Advanced solid tumor (2 trials)
• Asthma (2 trials)
• Breast cancer (2 trials)

New Research Horizons in Pittsburgh

This month, Pittsburgh saw the opening of 22 new clinical trials, a slight decrease from the 24 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Pittsburgh, PA, to 1,186 across 391 research facilities, underscoring the city's robust research landscape.

June brings several high-profile new trials to Pittsburgh, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Kallyope Inc. is initiating a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Also from Kallyope Inc., NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," seeks 1,000 participants. This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," a long-term study involving 1,400 participants. The goal is to better understand the health, development, and everyday experiences of people with Down syndrome of all ages over time.
• The VA Office of Research and Development is leading NCT07645274, "Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)." This randomized controlled trial aims for 268 participants to test the effectiveness of a peer-facilitated patient navigation program to improve mental healthcare experiences and outcomes for under-supported Veterans.
• The American Society of Pain and Neuroscience, Inc. is sponsoring a Phase 2 study, NCT07624279, "nVNS, CBD, and SoC for Persistent Post-Traumatic Headache," seeking 80 participants. This trial investigates if cannabidiol (CBD) or vagus nerve stimulation reduce persistent post-traumatic headache frequency more than traditional oral headache medications.
• The University of Alabama at Birmingham is leading a Phase 2b trial, NCT07674745, "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis," involving 52 participants. This study will compare the effectiveness and safety of a multi-component autoantibody reduction therapy for patients with progressive idiopathic pulmonary fibrosis (IPF).

New trials this month are exploring a range of conditions, with the most frequent being alcohol use (1 trial), anxiety (1 trial), atrial fibrillation (AF) (1 trial), ADHD (1 trial), brain cancer (1 trial), chromosome disorders (1 trial), cortical excitability (1 trial), diagnoses of depression (1 trial), Down syndrome (1 trial), and dry eye (1 trial). Drug trials account for the largest share of new studies, with 13 new drug trials, followed by 7 device trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 2 of the 22 new trials launched this month are actively seeking healthy volunteers. Across Pittsburgh, a total of 119 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 13 of these healthy volunteer opportunities are closing within the next 90 days.

Pittsburgh's Leading Research Hubs

Pittsburgh is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Pittsburgh (138 trials)
• University of Pittsburgh Medical Center (133 trials)
• University of Pittsburgh Cancer Institute (UPCI) (89 trials)
• UPMC Hillman Cancer Center (79 trials)
• Allegheny General Hospital (67 trials)
• Children's Hospital of Pittsburgh of UPMC (58 trials)
• UPMC Children's Hospital of Pittsburgh (46 trials)
• UPMC-Passavant Hospital (37 trials)
• Allegheny Health Network (34 trials)
• UPMC-Saint Clair Hospital Cancer Center (29 trials)
• UPMC-Shadyside Hospital (26 trials)

These institutions offer a broad spectrum of research, with a strong focus on oncology at facilities like UPCI, UPMC Hillman Cancer Center, and UPMC-Saint Clair Hospital Cancer Center, alongside general medical research at the University of Pittsburgh and UPMC, and pediatric studies at Children's Hospital of Pittsburgh.

Who Can Participate? Eligibility and Demographics

Participation in clinical trials is open to a diverse range of individuals. Of the 22 new trials launched this month, 19 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, and 2 are female-only. Academic institutions continue to play a vital role in Pittsburgh's research ecosystem, with Carnegie Mellon University and Johns Hopkins University sponsoring new studies this month. Industry sponsors like Kallyope Inc. are also driving significant research efforts.

Expanding Your Search: Nearby Pennsylvania Cities

While Pittsburgh offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Pennsylvania. Cities with active trials include Philadelphia (27 trials), Smithfield (3 trials), Allentown (3 trials), Erie (2 trials), Duncansville (2 trials), Bethlehem (2 trials), Scottdale (2 trials), and Monroeville (1 trial).

As we move through June, Pittsburgh's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.